Propanc Health Group Corp. (PPCH) Releases Study Results for Lead Product, Confirms Potential to Fight Certain Cancer Types
Propanc Health Group Corp. (OTCQB: PPCH) is an emerging healthcare company focused on the development of new and proprietary treatments for cancer patients suffering from solid tumors, such as those resulting from pancreatic, ovarian, and colorectal cancers. The company recently announced results from studies for its lead product, PRP, confirming a synergistic response to a broad range of cancer indications, including kidney, melanoma, brain, prostate, liver, uterine and lung cancers. The data provides compelling evidence that PRP has the potential to fight a broad range of cancer types, some with significant unmet medical needs. The company will continue to investigate…